Logotipo do repositório
 

Publicação:
Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1

dc.contributor.authorBoelen, Lies
dc.contributor.authorDebebe, Bisrat
dc.contributor.authorSilveira, Marcos [UNESP]
dc.contributor.authorSalam, Arafa
dc.contributor.authorMakinde, Julia
dc.contributor.authorRoberts, Chrissy H.
dc.contributor.authorWang, Eddie C.Y.
dc.contributor.authorFrater, John
dc.contributor.authorGilmour, Jill
dc.contributor.authorTwigger, Katie
dc.contributor.authorLadell, Kristin
dc.contributor.authorMiners, Kelly L.
dc.contributor.authorJayaraman, Jyothi
dc.contributor.authorTraherne, James A.
dc.contributor.authorPrice, David A.
dc.contributor.authorQi, Ying
dc.contributor.authorMartin, Maureen P.
dc.contributor.authorMacallan, Derek C.
dc.contributor.authorThio, Chloe L.
dc.contributor.authorAstemborski, Jacquie
dc.contributor.authorKirk, Gregory
dc.contributor.authorDonfield, Sharyne M.
dc.contributor.authorBuchbinder, Susan
dc.contributor.authorKhakoo, Salim I.
dc.contributor.authorGoedert, James J.
dc.contributor.authorTrowsdale, John
dc.contributor.authorCarrington, Mary
dc.contributor.authorKollnberger, Simon
dc.contributor.authorAsquith, Becca
dc.contributor.institutionImperial College London
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversity of London
dc.contributor.institutionInternational AIDS Vaccine Initiative Human Immunology Laboratory
dc.contributor.institutionLondon School of Hygiene and Tropical Medicine
dc.contributor.institutionCardiff University School of Medicine
dc.contributor.institutionUniversity of Oxford
dc.contributor.institutionOxford NIHR Biomedical Research Centre
dc.contributor.institutionUniversity of Cambridge
dc.contributor.institutionFrederick National Laboratory for Cancer Research
dc.contributor.institutionJohns Hopkins University
dc.contributor.institutionRho
dc.contributor.institutionSan Francisco Department of Public Health
dc.contributor.institutionUniversity of Southampton
dc.contributor.institutionNational Cancer Institute
dc.contributor.institutionMIT and Harvard
dc.date.accessioned2019-10-06T16:55:02Z
dc.date.available2019-10-06T16:55:02Z
dc.date.issued2018-01-01
dc.description.abstractKiller cell immunoglobulin-like receptors (KIRs) are expressed predominantly on natural killer cells, where they play a key role in the regulation of innate immune responses. Recent studies show that inhibitory KIRs can also affect adaptive T cell–mediated immunity. In mice and in human T cells in vitro, inhibitory KIR ligation enhanced CD8+ T cell survival. To investigate the clinical relevance of these observations, we conducted an extensive immunogenetic analysis of multiple independent cohorts of HIV-1–, hepatitis C virus (HCV)–, and human T cell leukemia virus type 1 (HTLV-1)–infected individuals in conjunction with in vitro assays of T cell survival, analysis of ex vivo KIR expression, and mathematical modeling of host-virus dynamics. Our data suggest that functional engagement of inhibitory KIRs enhances the CD8+ T cell response against HIV-1, HCV, and HTLV-1 and is a significant determinant of clinical outcome in all three viral infections.en
dc.description.affiliationDepartment of Medicine Imperial College London
dc.description.affiliationFaculty of Engineering São Paulo State University—UNESP
dc.description.affiliationInstitute for Infection and Immunity St. George’s University of London
dc.description.affiliationInternational AIDS Vaccine Initiative Human Immunology Laboratory
dc.description.affiliationClinical Research Department London School of Hygiene and Tropical Medicine
dc.description.affiliationDivi-sion of Infection and Immunity Cardiff University School of Medicine
dc.description.affiliationNuffield Department of Medicine University of Oxford
dc.description.affiliationOxford NIHR Biomedical Research Centre
dc.description.affiliationImmunology Division Department of Pathology University of Cambridge
dc.description.affiliationCancer and Inflammation Program Leidos Biomedical Research Inc. Frederick National Laboratory for Cancer Research
dc.description.affiliationJohns Hopkins University
dc.description.affiliationRho
dc.description.affiliationSan Francisco Department of Public Health
dc.description.affiliationFaculty of Medicine University of Southampton
dc.description.affiliationDivision of Cancer Epidemiology and Genetics National Cancer Institute
dc.description.affiliationRagon Institute of MGH, MIT and Harvard
dc.description.affiliationUnespFaculty of Engineering São Paulo State University—UNESP
dc.description.sponsorshipWisconsin Turfgrass Association
dc.description.sponsorshipNational Institutes of Health
dc.description.sponsorshipWellcome Trust
dc.description.sponsorshipInstitute for National Strategic Studies
dc.description.sponsorshipLeukemia and Lymphoma Research
dc.description.sponsorshipSeventh Framework Programme
dc.description.sponsorshipHorizon 2020
dc.description.sponsorshipMedical Research Council Canada
dc.description.sponsorshipNational Institute on Drug Abuse
dc.description.sponsorshipNational Institute of Child Health and Human Development
dc.description.sponsorshipIdWisconsin Turfgrass Association: 090323/Z/09/Z
dc.description.sponsorshipIdNational Institutes of Health: 100326Z/12/Z
dc.description.sponsorshipIdWellcome Trust: 103865Z/14/Z
dc.description.sponsorshipIdInstitute for National Strategic Studies: 105609/Z/14/Z
dc.description.sponsorshipIdLeukemia and Lymphoma Research: 15012
dc.description.sponsorshipIdSeventh Framework Programme: 317040
dc.description.sponsorshipIdHorizon 2020: 695551
dc.description.sponsorshipIdMedical Research Council Canada: G1001052
dc.description.sponsorshipIdMedical Research Council Canada: J007439
dc.description.sponsorshipIdNational Institute on Drug Abuse: K24-AI118591
dc.description.sponsorshipIdMedical Research Council Canada: MR/L018373/L
dc.description.sponsorshipIdMedical Research Council Canada: MR/M019829/1
dc.description.sponsorshipIdMedical Research Council Canada: MR/P001602/1
dc.description.sponsorshipIdNational Institutes of Health: R01 DA13324
dc.description.sponsorshipIdNational Institute on Drug Abuse: R01-DA-12568
dc.description.sponsorshipIdNational Institute of Child Health and Human Development: R01-HD-41224
dc.description.sponsorshipIdNational Institute on Drug Abuse: U01-DA-036297
dc.identifierhttp://dx.doi.org/10.1126/sciimmunol.aao2892
dc.identifier.citationScience Immunology, v. 3, n. 29, 2018.
dc.identifier.doi10.1126/sciimmunol.aao2892
dc.identifier.issn2470-9468
dc.identifier.lattes8286209184527011
dc.identifier.scopus2-s2.0-85056420369
dc.identifier.urihttp://hdl.handle.net/11449/189875
dc.language.isoeng
dc.relation.ispartofScience Immunology
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.titleInhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell–mediated control of HIV-1, HCV, and HTLV-1en
dc.typeArtigo
dspace.entity.typePublication
unesp.author.lattes8286209184527011
unesp.departmentEngenharia Mecânica - FEBpt

Arquivos